Lung Cancer in 2022 and Beyond

Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include clinical decision-making, the extent emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.

November 4–5, 2022
Corey Langer MD Scientific Leader Faculty Chair Aptitude Health

FACULTY CHAIR

Corey Langer, MD, FACP

University of Pennsylvania, PA, US

Faculty Members

Shirish Gadgeel, MD
Henry Ford Health, Detroit, MI, US

Paul Bunn, MD, FASCO
University of Colorado School of Medicine, Aurora, CO, US

Martin Edelman, MD
Fox Chase Cancer Center, Philadelphia, PA ,US

Antoinette Wozniak, MD, FACP, FASCO
UPMC Hillman Cancer Center, Pittsburgh, PA, US

Ignacio I. Wistuba, MD
MD Anderson Cancer Center, Houston, TX, US

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, US

Natasha Leighl, MD, FASCO
University of Toronto, Ontario, Canada

Paul Paik, MD
Memorial Sloan Kettering Cancer Center, New York, NY, US

Jamie Chaft, MD
Memorial Sloan Kettering Cancer Center, New York, NY, US

Fred Hirsch, MD, PhD
The Tisch Cancer Institute, New York, NY, US

Agenda

Download the meeting agenda

View Agenda

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Prognostic and Predictive Biomarkers in NSCLC: Pathologic Implications, Clinical and Research Relevance
  • New Directions for EGFR-Mutant NSCLC
  • EGFR (Less Common Mutations, Including Exon 20 Insertions)
  • Emergence of Immunotherapy and Bispecifics in SCLC
  • Therapeutic Landscape for Fusion-Positive NSCLC (ALK, ROS1, NTRK, RET)
  • Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, HER2, MET, and BRAF
  • Promising New Targets/Agents in Lung Cancer: ADCs and Beyond
  • Perioperative Immunotherapy in Early NSCLC
  • Immunotherapy in Unresectable Stage III NSCLC
  • First-Line Immunotherapy in Metastatic NSCLC: Single Agent or Combination?
  • New Directions for Second-Line Therapy
  • Emergence of Immunotherapy and New Agents in SCLC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.